Development of membrane-targeting TPP⁺-chloramphenicol conjugates to combat methicillin-resistant staphylococcus...

Area of Science:

• Medicinal Chemistry
• Antimicrobial Resistance
• Drug Discovery

Background:

• Drug-resistant bacterial infections pose a significant global health threat.
• The efficacy of established antibiotics, such as chloramphenicol (CL), is diminishing due to widespread bacterial resistance.
• There is an urgent need for novel therapeutic agents to combat resistant pathogens.

Purpose of the Study:

• To design, synthesize, and evaluate novel triphenylphosphonium chloramphenicol conjugates (TPP+-CL) as potential antimicrobial agents.
• To assess the antibacterial activity of TPP+-CL compounds against clinically relevant resistant bacterial strains.
• To investigate the in vitro and in vivo efficacy and safety profile of lead TPP+-CL candidates.

Main Methods:

• Synthesis of a series of triphenylphosphonium chloramphenicol conjugates (TPP+-CL).
• Determination of minimum inhibitory concentrations (MICs) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA).
• Evaluation of bactericidal kinetics, bacterial resistance development, and in vivo efficacy in a mouse infection model.

Main Results:

• Compounds 39 and 42 demonstrated potent antibacterial activity against MRSA strains, with MIC values of 1-2 μg/mL, whereas chloramphenicol was inactive.
• The TPP+-CL conjugates exhibited rapid bactericidal effects and low toxicity in vitro.
• Compound 39 showed comparable or superior in vivo efficacy to vancomycin in a mouse MRSA infection model, with no observed toxicity.

Conclusions:

• Novel TPP+-CL conjugates represent a promising class of compounds for combating drug-resistant bacterial infections, particularly MRSA.
• These conjugates overcome the resistance limitations of the parent chloramphenicol molecule.
• TPP+-CL compounds offer a potential therapeutic strategy with favorable efficacy and safety profiles for treating serious bacterial infections.